Table 3 Univariate and multivariate analysis of pr4gression-free survival (PFS) (n = 90)
Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Sex | ||||
Male vs. female | 1.0 vs. 0.72 (0.42–1.24) | 0.236 | ||
Age | ||||
< 63 y.o vs. ≥63 y.o | 1.0 vs. 0.82 (0.48–1.40) | 0.472 | ||
ECOG PS | ||||
0 vs. 1,2 | 1.0 vs. 0.66 (0.21–2.14) | 0.490 | ||
Site of primary tumor | ||||
RCC vs. LCRC | 1.0 vs. 0.88 (0.51–1.52) | 0.643 | ||
Differentiated-type | ||||
yes vs. no | 1.0 vs. 1.78 (0.75–4.22) | 0.188 | ||
Synchronous mets | ||||
yes vs. no | 1.0 vs. 0.61 (0.29–1.30) | 0.201 | ||
Sites of metastasis | ||||
Non-liver vs. liver | 1.0 vs. 1.84 (1.06–3.20) | 0.031 | 1.0 vs. 3.26 (1.57–6.77) | 0.002 |
Non-lung vs. lung | 1.0 vs. 1.17 (0.68–2.00) | 0.567 | ||
Non-LN vs. LN | 1.0 vs. 0.67 (0.37–1.20) | 0.177 | ||
Non-P vs. P | 1.0 vs. 0.95 (0.51–1.78) | 0.878 | ||
Number of metastases | ||||
1 vs. ≥2 | 1.0 vs. 0.87 (0.51–1.50) | 0.628 | ||
Primary resection | ||||
yes vs. no | 1.0 vs. 2.00 (1.09–3.66) | 0.024 | 1.0 vs. 2.13 (1.05–4.29) | 0.035 |
Prior L-OHP | ||||
yes vs. no | 1.0 vs. 0.75 (0.35–1.60) | 0.457 | ||
ALP (/) | ||||
≤ ULN vs. >ULN | 1.0 vs. 1.07 (0.56–2.04) | 0.836 | ||
LDH (/IU) | ||||
≤ ULN vs. >ULN | 1.0 vs. 1.27 (0.74–2.21) | 0.387 | ||
CRP (mg/dl) | ||||
≤ ULN vs. >ULN | 1.0 vs. 2.35 (1.32–4.17) | <0.001 | 1.0 vs. 1.57 (0.79–3.10) | 0.196 |
CEA | ||||
≤ ULN vs. >ULN | 1.0 vs. 0.90 (0.49–1.65) | 0.735 | ||
CA19-9 | ||||
≤ ULN vs. >ULN | 1.0 vs. 1.63 (0.95–2.80) | 0.076 | ||
RAS status | ||||
Wild-type vs. mutant | 1.0 vs. 1.36 (0.79–2.32) | 0.264 | 1.0 vs. 2.01 (1.07–3.76) | 0.030 |
PIK3CA status | ||||
Wild-type vs. mutant | 1.0 vs. 1.00 (0.36–2.77) | 0.993 | 1.0 vs. 0.66 (0.21–2.03) | 0.466 |
BRAF status | ||||
Wild-type vs. mutant | 1.0 vs. 1.60 (0.68–3.75) | 0.285 | 1.0 vs. 3.87 (1.38–10.9) | 0.010 |